Şeyda Gündüz

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

Chemotherapy Versus Placebo, Breast Oncology, Oncology +7

Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer

Şeyda Gündüz, Hasan Mutlu, Deniz Tural et al. · Asia-Pacific Journal of Clinical Oncology · 2015 · 64 citations

Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study.

Meral Günaldı, Sema Sezgin Göksu, Di̇lek Erdem et al. · PubMed · 2015 · 51 citations · Full text

A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study

Umut Rıza Gündüz, Meral Günaldı, Nilgün Işıksaçan et al. · Molecular and Clinical Oncology · 2016 · 46 citations · Full text

Breast Oncology, Molecular Biology, Pathology +21

Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer

Derya Kıvrak Salim, Hasan Mutlu, MELEK KARAKURT ERYILMAZ et al. · Molecular and Clinical Oncology · 2015 · 37 citations · Full text

Cancer Immunosurveillance, Nlr ≤2.93, Medicine +13